SSTR2 and acromegaly: Paltusotine (Crinetics Pharmaceuticals; San Diego, CA) is currently under US Food and Drug Administration (FDA) review for the treatment of acromegaly and, if approved, will be the first once-daily, oral, nonpeptide, selective somatostatin receptor type 2 agonist available for this indication [46–49].